To verify whether FGFR1 could be a potential therapeutic target for BPD, the effects of the FGFR1 inhibitor (AZD4547) on hyperoxia-induced BPD was evaluated. This evidence concerns the gene FGFR1 and bronchopulmonary dysplasia.